High-Dose Diazepam Controls Severe Dyskinesia in Anti-NMDA Receptor Encephalitis.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
21
03
2020
accepted:
21
09
2020
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
ppublish
Résumé
Because there is no standard treatment to control dyskinesia in anti-NMDA receptor (NMDAR) encephalitis, we analyzed the therapeutic efficacy of high-dose diazepam in dyskinesia associated with NMDAR encephalitis. We reviewed patients with NMDAR encephalitis with dyskinesia who were admitted to Seoul National University Hospital between November 2012 and July 2018. High-dose diazepam was administered orally or via a nasogastric tube 3-6 times a day. We assessed the treatment effect by comparing dyskinesia severity between the first day of the highest dose of diazepam and one week after the treatment. Among 68 patients with NMDAR encephalitis during the study period, 33 patients were treated with enteral diazepam (ranging from 6 to 180 mg) to control dyskinesia, along with immunotherapy. The severity of dyskinesia improved from average grade 2.4 ± 0.6 to 1.1 ± 0.7 after 1 week of the highest dose of diazepam (mean severity change -1.4 ± 0.6, 95% confidence interval -1.2 to -1.6; Dyskinesia in NMDAR encephalitis improved after treatment with enteral diazepam without significant side effects. This study suggests that enteral diazepam could be a treatment option for control dyskinesia in NMDAR encephalitis. This study provides Class IV evidence that for patients with dyskinesias associated with NMDAR encephalitis, enteral diazepam is effective and safe in dyskinesia control.
Identifiants
pubmed: 34484945
doi: 10.1212/CPJ.0000000000001001
pii: NEURCLINPRACT2020052787
pmc: PMC8382394
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e480-e487Informations de copyright
© 2021 American Academy of Neurology.
Références
Neurotherapeutics. 2016 Oct;13(4):824-832
pubmed: 27215218
Acta Neuropathol. 2009 Dec;118(6):737-43
pubmed: 19680671
Ann Neurol. 2019 Mar;85(3):352-358
pubmed: 30675918
Acta Neurol Scand. 2008 Aug;118(2):69-86
pubmed: 18384456
JAMA. 1966 Jan 17;195(3):222-4
pubmed: 5951806
Curr Neurol Neurosci Rep. 2011 Jun;11(3):298-304
pubmed: 21331529
Mov Disord. 2002 Sep;17(5):853-66
pubmed: 12360534
Drugs. 2000 Mar;59(3):487-95
pubmed: 10776831
Brain. 2010 Jun;133(Pt 6):1655-67
pubmed: 20511282
Lancet Neurol. 2010 Jan;9(1):67-76
pubmed: 19962348
Neurology. 2014 Jul 8;83(2):142-50
pubmed: 24920861
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
J Neuroimmunol. 2016 Sep 15;298:178-80
pubmed: 27609293
Neurology. 2016 May 3;86(18):1683-91
pubmed: 27037228
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):724-726
pubmed: 30032119
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Mov Disord. 2011 Feb 1;26(2):351-2
pubmed: 21412839
Nat Neurosci. 2000 Dec;3(12):1274-81
pubmed: 11100148
J Neuroimmunol. 2016 Oct 15;299:107-111
pubmed: 27725107
Proc Staff Meet Mayo Clin. 1963 May 22;38:203-12
pubmed: 13955116
ACS Chem Neurosci. 2014 Apr 16;5(4):253-60
pubmed: 24552479
N Engl J Med. 2009 Jul 2;361(1):62-72
pubmed: 19571284
Neurology. 2017 Jan 24;88(4):366-370
pubmed: 28003505
Ann Clin Transl Neurol. 2018 Mar 23;5(5):598-605
pubmed: 29761122
FEBS Lett. 2011 Dec 1;585(23):3699-709
pubmed: 21419125
Trends Neurosci. 2016 May;39(5):300-310
pubmed: 27130657
Cochrane Database Syst Rev. 2004;(1):CD003954
pubmed: 14974046
Mov Disord. 2014 Oct;29(12):1539-42
pubmed: 25154478
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Acta Psychiatr Scand. 1988 Sep;78(3):396-8
pubmed: 3195360